anti-mesothelin CAR vector-transduced autologous T lymphocytes

Anti-meso-CAR vector transduced T cells are a form of chimeric antigen receptor (CAR) T-cell therapy specifically engineered to target mesothelin, a protein highly expressed in several types of solid tumors. This therapy involves genetically modifying a patient's own T lymphocytes (autologous T cells) with a retroviral vector that encodes a chimeric antigen receptor designed to recognize mesothelin on cancer cells[1][2]. The CAR construct consists of three main parts: - An extracellular antigen-binding domain (single-chain variable fragment or scFv) that specifically recognizes mesothelin - A hinge region connecting the scFv to intracellular components - An intracellular signaling domain derived from T cells or natural killer cells (such as 4-1BB and CD28)[3] Anti-meso-CAR vector transduced T cells work by recognizing mesothelin, a 40 kDa GPI-anchored plasma membrane protein expressed on various cancer cells. Mesothelin is particularly overexpressed in mesothelioma, pancreatic cancer, and ovarian cancer, making it an attractive target for immunotherapy[5]. When the CAR on the modified T cells binds to mesothelin on cancer cells, it triggers T-cell activation independent of MHC molecule restriction. This activation leads to: - Phosphorylation of ITAM (immunoreceptor tyrosine-based activation motif) - Cytokine secretion - CAR-T cell proliferation - Cytotoxic effects through perforin and granzymes - Activation of death receptor signaling via Fas/FasL or TNF/TNF-α pathways[3]

Other names

anti-mesothelin CAR vector-transduced autologous T-lymphocytes